Objectives: This paper aims to identify relevant potential predictors of medical genetic counseling for breast cancer (MGC-BC) in primary care and to develop a comprehensive questionnaire to study MGC-BC. Methods: A scoping review was conducted to identify the predictors of MGC-BC among primary care physicians. Relevant articles were identified in selected databases (PubMed, Embase, CINAHL, ISI Web of Science, PsycINFO, and Cochrane CENTRAL) and 4 selected relevant electronic journals. Results: An inductive analysis of the 193 quantitatively tested variables, conducted by 3 researchers, showed that 6 conceptual categories of determinants, namely (1) demographic, (2) organizational, (3) experiential, (4) professional, (5) psychological, and (6) cognitive, influence MGC-BC practices. Conclusion: There is a scarcity of literature addressing the medical behavior determinants of MGC-BC. Future research is needed to identify effective strategies put into action to support the integration of MGC-BC in primary care medical practices and routines. However, our results shed light on 2 levels of actions that could improve genetic counseling services in primary care: (1) medical training and educational efforts emphasizing family history collection (individual level), and (2) clarification of roles and responsibilities in ordering and referral practices in genetic counseling and genetic testing for better healthcare management (organizational level).

Breast cancer is the most frequently diagnosed cancer among women (23% of all cancers) and the leading cause of cancer mortality among women worldwide [1]. A woman in the developed world has a lifetime risk of developing breast cancer of approximately 9-11% [2]. The estimated global economic burden of new breast cancer cases in 2009 was USD 28 billion, representing associated medical costs as the largest fraction (46%), followed by productivity losses (27%), and non-medical service costs (27%) [3]. Genetic research identified pathogenic mutations in BRCA1 and BRCA2 genes in 5-10% of hereditary breast cancer, and recent genetic discoveries showed more susceptible genes including TP53 mutations in Li-Fraumeni syndrome, STK11 mutations in Peutz-Jeghers syndrome, and PTEN mutations in Cowden syndrome [4]. Thus, an important proportion of the social and economic burden arising from breast cancer can be reduced and limited by implementing effective evidence-based strategies such as genetic counseling, risk management and surveillance, and early-stage tumor detection and management targeting women at moderate or high risk for breast cancer [5,6,7].

However, despite major advances in understanding the familial and hereditary risk factors for breast cancer development [8,9,10] and their translation into more accurate screening as well as preventive and therapeutic health interventions [11], there is still a need for integrating genetic services into medical practices [12], and more generally, into any context where the genetic counseling process is a critical component [13,14,15]. Indeed, the genetic counseling process includes effective assessment and communication of individual genetic risks as well as surveillance of at-risk patients. Thus, genetic counseling not only favors the detection of breast cancer at early stages, thus improving prognosis and survival and reducing mortality as well as the economic and social burden associated with breast cancer [6], but also fosters optimal treatment, surgery, and clinical follow-up for newly diagnosed breast cancer patients [16].

According to O'Daniel [17], genetic counseling for breast cancer is a combination of 2 clinical approaches: the risk prediction (RP) [18,19] and the risk communication (RC) [20,21]. This paper will consider genetic counseling for breast cancer exclusively from the point of view of medical doctors, thus referring to it as medical genetic counseling for breast cancer (MGC-BC) to differentiate it from genetic counseling provided by genetic counselors. We support that for an effective genetic counseling both healthcare providers (medical doctors and genetic counselors) have to be involved in an interdisciplinary collaboration. However, for the purpose of this paper, we will explore exclusively studies related to medical doctors. The MGC-BC process can be defined as a complex process [14,22] that includes collecting and interpreting the familial and individual medical history to identify subjects at risk for hereditary breast cancer [13], ordering cancer susceptibility genetic tests or referring patients to other providers of these tests [23], providing risk information and risk management options [11], and facilitating informed decisions and adaptation to personal risk by increasing personal control and minimizing psychological distress [24].

Systematic reviews on genetic counseling have extensively studied the patient's perspective and have shown the impact of the physician's clinical behaviors on patient outcomes such as cognitive aspects (risk understanding and interpretation) and clinical decisions (testing, genetic service utilization, and treatment compliance) [11,14,25,26,27]. However, fewer studies have explored the MGC-BC process from the medical point of view. Therefore, knowledge about effective strategies for physicians to improve the effectiveness of the MGC-BC process is rather limited. Thus, we have performed a scoping review to identify factors (facilitators and barriers), shown as having a significant impact on MGC-BC performance among medical doctors, in order to derive evidence-based recommendations that may help research and decision making to support more effective MGC-BC practices in primary care and to develop a comprehensive framework and a questionnaire to be used in future research on MGC-BC.

Data Collection

A scoping review of counselor-based literature on RP and RC in breast cancer genetic counseling was conducted to identify major steps of these processes as well as their determinants.

Our approach followed established methods for a scoping literature review [28] and was based upon 5 stages: identifying the research question, identifying relevant studies, selecting studies, charting the data, and collecting, summarizing, and reporting the results. Our research question was: Which are the factors that impact on the use of RP models and RC strategies among medical doctors? To answer this question, we built a selection strategy for identifying relevant studies. Only papers using a quantitative design and published in health sciences were considered. We did not include qualitative studies, since they may affect the generalizability of our results.

Our search strategy involved 4 separate search activities, namely (1) a search for the most relevant keywords, (2) a search for reference lists from literature reviews and systematic reviews on the topic to assess the amount of relevant publications on the topic and evaluate the relevance of our study, (3) an electronic database search, and (4) a hand search in selected electronic journals. A specialist librarian developed a search strategy and was given a list of keywords proposed by the researchers. Relevant databases (table 1) were searched for published articles using MeSH and free text keywords in various combinations using the Boolean operators ‘AND' and ‘OR' (online suppl. table 1; for online suppl. material, see www.karger.com/doi/10.1159/000362358).

Table 1

List of electronic databases used in this study

List of electronic databases used in this study
List of electronic databases used in this study

Next, we performed a systematic hand search of all issues of selected electronic relevant journals in the domain of genetic counseling, namely Medical Genetics, Journal of Genetic Counseling, American Journal of Preventive Medicine, Preventive Medicine, and American Journal of Medical GeneticsPart A, Part B, and Part C. We also performed a systematic hand search in the reference list of each selected article to identify additional relevant articles that had not been identified via the electronic search strategy.

Because of the scarcity of literature on familial breast cancer, we extended our research to other cancers and other genetic diseases to capture all predictors and propose recommendations for practice and research. No time period restriction had been imposed for identifying relevant articles. We invited an advisory committee of researchers and clinicians for a 1-day meeting. Based on the research objective, they had to identify eligibility (inclusion and exclusion) criteria to be applied to determine which studies should be considered for inclusion within the review. Indeed, they are fundamental to collecting a rigorous set of data. Thus, for the scoping review, articles were selected based on the inclusion and exclusion criteria presented in table 2.

Table 2

Inclusion and exclusion criteria

Inclusion and exclusion criteria
Inclusion and exclusion criteria

The articles retrieved were exported to the EndNote X2 program. We built an Excel information extraction form to (1) compile concepts and measures used to study determinants of RP and RC among physicians and (2) present descriptive statistics on studies retrieved for the scoping review.

Data Analysis

Data from all extracted papers were read and analyzed at each step by 2 independent researchers, and the results were validated by the research team coordinator (fig. 1). An inter-coder reliability score was calculated at each step. The most often used approach is to randomly select 10% of the articles and have them analyzed separately by 2 independent researchers, followed by evaluation of the consistency index [29,30]. As pointed out by some authors, Cohen's kappa is the measure of choice for interceder agreement [30,31,32,33]. As widely used in this type of study, data interpretation was carried out using Landis and Koch's categorization and reference kappa statistic strength of agreement as follows: <0% as poor, 0.1-20% as slight, 21-40% as fair, 41-60% as moderate, 61-80% as substantial, and 81-100% as almost perfect [34]. We established the acceptable score at 70% which has been shown to be the most appropriate in exploratory studies [35].

Fig. 1

Flow diagram.

The information extracted included the population under study (medical doctors), study design (objectives, methodology, data collection, and analysis), health topic(s) (breast cancer, other cancers, and other genetic diseases), dependent variables (RP, RC, or both) and independent variables (facilitators and barriers), including their conceptual and operational definitions. Quantitative descriptive analysis and qualitative content analysis were then performed. Content analysis was employed to examine the determinants of medical behaviors. This method of analysis was selected as a helpful means through which our large data set could be systematically scrutinized and categorized according to the theoretical articulation based on the social cognitive theories [36] and the value creation framework as applied to knowledge [37]. This theoretical articulation was used to code the findings and to structure the classification and the abstraction of the identified physician-associated factors in a 2-step conceptual analysis: (1) a conceptual categorization and (2) a conceptual abstraction. At first, we established the existence and frequency of variables (determinants) used in the econometric models of each included study. Thus, we were able to determine how many times each determinant was included in an econometric model and to categorize the effect it had on the dependent variable RP/RC (the direction of the effect). Secondly, we grouped the identified determinants in conceptual categories according to the theoretical articulation to propose recommendations for practice and research.

This scoping review aimed to identify predictors of MGC-BC that may help provide recommendations for practice and research. Of the 147 retrieved articles, 31 studies, focused on health professional clinical behavior and using a quantitative methodology design, were selected.

Descriptive Analysis Results

The 31 selected studies were published between 1992 and 2010, with a median in 2006 (table 3). Studies were predominantly conducted in the United States (61%), the United Kingdom (10%), and the Netherlands (10%). Other countries represented were Australia, Canada, France, Mexico, and Switzerland. The populations were studied according to 2 perspectives: a unique specialty perspective [29% of the studies adopted a specific health professional (e.g. general practitioner) perspective], and a multi-specialty perspective (61% adopted a comprehensive perspective, exploring multiple categories of health professionals). The number of participants ranged from 75 [18] to 1,795 [38], with a mean of 588 participants. Authors explored genetic RP through 2 perspectives: (a) ordering for a genetic test and (b) referral for genetic testing with/without genetic counseling. However, genetic risk assessment based on family and individual history was always included as part of the initial assessment of patient risk level categorization. In general, studies did not provide any information on the prediction model used by the medical doctor to assess the patient's level of risk [e.g. Manchester Scoring System, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model, Gail model]. Indeed, we extracted information on factors that might impact on the referral or prescription of genetic testing with the underlying assumption that medical doctors always collect and interpret family history to clinically assess the genetic risk before deciding on the relevance of ordering genetic tests.

Table 3

Characteristics of the studies included in this review

Characteristics of the studies included in this review
Characteristics of the studies included in this review

Our findings showed that only 6 among the 31 selected articles (19%) explored MGC-BC as a specific target, and 10 of the 31 articles (31%) integrated MGC-BC with other health topics, i.e. ovarian cancer, prostate cancer, etc. About 50% of the selected articles explored other types of cancers (e.g. colorectal cancer) or diseases (e.g. Huntington disease).

Studies explored genetic RP and RC as a comprehensive process in only 30% of the articles. Most articles analyzed the RC process to study the skills and abilities of medical doctors to communicate with their patients. The major interest behind most of these studies was to further investigate the patient-oriented approach and the shared decision-making process. Articles that analyzed RP mostly focused on the compliance of medical doctors with guidelines from genetic counseling professionals and the actual relevance of genetic referrals. The categories of health professionals were addressed as follows: 11 articles (38%) explored the clinical behaviors of primary care physicians exclusively, 15 articles considered multiple clinical specialties, and 4 articles included only specialists. However, it must be pointed out that there is no widely accepted definition of primary care physicians among the different studies, especially in the US where this term may include family physicians, internists, obstetricians, and pediatricians. European studies define primary care physicians more consistently as including family doctors and general practitioners (GPs) only.

MGC-BC Predictors

Due to the small number of studies on breast cancer, we decided to integrate the results generated from all 31 selected articles in our analysis. Thus, an inductive analysis of the 193 variables that were quantitatively tested to predict clinical behaviors in medical genetic counseling led to the identification of 6 major conceptual categories of determinants (table 4, fig. 2) having an impact on the performance of medical genetic counseling: (1) demographic, (2) organizational (3) experiential, (4) professional, (5) psychological, and (6) cognitive. The literature shows that medical genetic counseling based on family history is usually considered as equivalent to genetic RC. Genetic RP is mostly associated with genetic testing where, according to the country of practice, the clinician can order the genetic test (either as a public or private service) or must refer the patient to a genetic counseling and testing center to provide genetic counseling services and perform the test.

Table 4

Taxonomy of barriers and facilitators and their definitions

Taxonomy of barriers and facilitators and their definitions
Taxonomy of barriers and facilitators and their definitions
Fig. 2

Major predictors of MCG-BC.

Fig. 2

Major predictors of MCG-BC.

Close modal

Table 5 shows a synthesis of the barriers and facilitators after quantitative testing and classification into the 6 categories of factors mentioned above that are related to the 3 variables studied, namely: (1) RC, (2) RP via ordering a test, and (3) RP via referring a patient. We used a vote-counting method [39] which consists of the count of the significant effect directions by considering the same operational definition of the dependent variable. This method has been previously used in systematic reviews in medicine [40,41,42]. Our review shows that 60% of the categories of variables were considered in studies that integrated RP and RC in a comprehensive process.

Table 5

Number of quantitative significant barriers and facilitators of genetic counseling

Number of quantitative significant barriers and facilitators of genetic counseling
Number of quantitative significant barriers and facilitators of genetic counseling

RP Predictors

Ethnicity/Race. Self-identification as a member of an ethnic group was found to be a barrier to engage in a RP process [19,43]. Physicians who identified themselves as Asians, Asian Pacific Islanders, and Latino/African Americans were less likely to refer patients to a genetic center for genetic testing or to a genetic counselor. Because these doctors practiced in minority groups, some factors like paucity of resources and low health literacy (patient-related factors) may be considered as confusion bias. Thus, the evidences are not strong enough for this variable.

Religion. Self-identification as non-religious was found to be a facilitator for routinely offering DNA testing, notably with respect to pre-conceptional cystic fibrosis screening [44]. Another study found that religious affiliation was an inhibitor of ordering a genetic test [45]. It seems that there is not enough evidence to support the effect of this factor.

Healthcare Services Management. Some studies have identified that the availability of professional society guidelines [46] that favor genetic counseling [47] were positively associated with referrals for genetic testing. In addition, the accessibility of genetic testing services influenced medical doctors' provision of such services. Indeed, genetic counseling services that are poorly integrated with the daily routine of physicians' practice were one of the barriers discussed by Hindorff et al. [47] regarding RP. There is enough evidence that supports the effect of these types of predictors.

Diversity of Work Time-Sharing. The type of work time-sharing (work as a full-time faculty or in teaching/research) was also found to be a facilitator for RP. Being a medical doctor with a full-time appointment and working in teaching or research facilities was positively correlated with referring for genetic tests regarding various cancers (especially breast cancer) [19,43]. However, this category of factors has to be interpreted according to context, since genetic services and referral procedures may differ from one country to another. For example, in Australia, professional guidelines for GPs/family doctors are available and present clear information on the appropriate referral of patients to specialized familial cancer services where MGC-BC is offered [48]. The evidence for supporting these effects on RP is sufficient.

Openness to Innovation. Shields et al. [19] also found that acceptance of innovative practices and self-identification as an early adopter of new diagnostic tests had a positive impact on RP, including either referral for genetic counseling or ordering genetic tests. There is satisfying evidence to support the effect of this predictor on RP.

Clinical Skills. Clasen et al. [49] showed a positive association between the outcome expectancies by medical doctors and genetic test-ordering practices. Indeed, genetic testing practices were influenced by the fact that the performance of tests by medical doctors was recognized to decrease mortality or to detect the disease earlier effectively [49]. However, physicians' practices may reflect caution in ordering tests or a lack of knowledge of the appropriate indications for genetic testing (e.g. paucity of clinical guidelines, best practices or recommendations) [49]. There is significantly sufficient amount of evidence that supports the relation of this predictor with RP.

Self-Confidence: Emotional Comfort. The feeling of comfort related to patients and the feeling of comfort as related with the type of patient and the situation have both been shown to have an impact on RP. Verger et al. [50] conducted a study on genetic services for women with physical and mental impairments. The results revealed that feelings of discomfort in GPs when providing care to women with disabilities were strongly associated with providing less frequent breast cancer screenings to this specific group. Moreover, Clasen et al. [49] showed that physicians felt discomfort in performing cancer screening tests during patient visits for clinical complaints that were not related to cancer. The evidence regarding this predictor is enough to support its relation with RP.

Attitudes. A positive attitude towards the benefits of genetics on treatment of breast or colorectal cancer [19], towards genetic counseling and its implications on clinical decision making [18], and towards the accuracy of the tests [51] had a positive impact on RP practices. The evidence which supports these effects on RP seems sufficient.

Geographic Location. Literature has shown differences among geographic areas within the same country [51,52]. Practicing in communities of higher-socioeconomic status was found to be a facilitator for RP. Moreover, the regions of practice as defined by the language spoken were also found to have a significant effect on the ordering process (e.g. the French- and Italian- as opposed to the German-speaking regions in Switzerland) [51]. These differences could be explained by social factors such as cultural differences between ethnic groups, organizational factors such as a lower access to healthcare services among linguistic minority groups, or geographical factors such as living in an urban or rural/remote area. The evidence to support the effect of these predictors is adequate.

Organizational Affiliation. Dulai et al. [53] have found that physicians with independent practice association are less likely to recommend cancer screening compared with those affiliated with an integrated medical group. Because this study has been about colorectal cancer, it cannot be considered as a strong evidence for this effect regarding breast cancer.

Source of Information. Verger et al. [50] have reported a negative association between RP and assistance during consultation. Also, Foo et al. [54] reported an association between RP and the presence of attending specialists with respect to colorectal cancer patients. The evidence about these relations is not sufficient.

Self-Confidence: Perceived Knowledge Skills. Shields et al. [19] have found that feeling prepared and confident with genetic skills was positively associated with ordering a genetic test. The supporting evidence seems rather insufficient for this predictor.

Medical Knowledge: Training. A lack of training in genetic medicine is a barrier with respect to RP. Shields et al. [19] found this relationship between medical schools (and/or continuing medical education) training in clinical genetics and RP, for either ordering tests or referral practices. It seems that the evidence in this field is not strong enough to support these relations with respect to breast cancer.

RC Predictors

Age. Being a physician older than either 50 or 65 years of age was found to be a barrier to genetic counseling taken as a comprehensive process [55]. The study was about genetic counseling in general and not breast cancer specifically. Thus, the evidence seems pretty insufficient related to breast cancer.

Gender. Female physicians were more likely to communicate genetic risk including its assessment. One study found that male physicians were more likely to provide explicit information on genetic risks to cancer patients [56]. However, other studies found that male gender could be either a barrier or a facilitator on the RC or RP processes [53,57]. There is adequate evidence regarding female but not male physicians (gender of the medical practitioners as a predictor for RC).

Organizational Affiliation. Kaplan et al. [43] also found a negative association between the initiation of counseling and working in a Health Maintenance Organization. Their study has been about breast cancer, and the findings could be considered as a strong evidence for this type of predictor.

Geographic Location. Keller et al. [51] found that clinical geneticists from Northern and Western European countries had a better experience with counseling and RC than those from Southern and Eastern countries of the continent. This result cannot be considered as a strong evidence for this predictor.

Number of Years of Practice/Seniority. A positive association between RC and the number of practicing years was found in Wolf et al. [58]. More studies about breast cancer should be accomplished to consider the results as a strong enough support for this effect.

Self-Confidence: Perceived Communication Skills. Geller et al. [59] found that a high level of confidence and tolerance to ambiguity were positively associated with RC. Their study was about cystic fibrosis, and this finding cannot be assumed strong enough as an evident.

Attitude. Adopting a paternalistic attitude was positively associated with RC [56]. The literature also showed that RC is positively associated with a positive attitude towards genetic susceptibility testing [60], the benefits of good communication [56], and death (i.e. the acceptance of death) [56]. However, negative attitudes toward health insurance issues (i.e. loss of insurance) related to genetic testing for cancer susceptibility [61] were found to be barriers to RC. These studies were about general chronic diseases and cancers, so their findings are not strong evidences for breast cancer genetic counseling.

Perceived Roles. The perceived role of the professional had been identified as a predictor of RC. Escher and Sapino [60] found that physicians who felt that they have an active role in the pre-test procedure, the disclosure of results, and long-term follow-up were better in RC. Though, Kaplan et al. [43] found that the perceived role of physicians is negatively associated with the initiation of counseling. The evidence is strong enough.

Medical Knowledge: Medical Specialty. There are many studies that have explored the relation between the specialty of the doctors and RC or RP. Keating et al. [62] found that surgeons and geneticists were less likely than medical oncologists to always/usually report covering all aspects of RC, such as the benefits and limitations of close surveillance, the possibility of a psychological reaction, or sharing test results with family members. However, geneticists reported the highest rates of counseling [62]. Moreover, there was evidence that physicians in other specialties are more likely to engage in RC, namely oncologists [61], obstetricians/gynecologists [20,63,64], and obstetricians [38]. The evidence in this regard seems strong enough.

Medical Knowledge: Training. Physicians who had taken one course or more in genetics were more likely to engage in RC [21,56]. Also, Lazcano-Ponce et al. [56 ]found that when physicians had received training in bioethics, their RC was characterized by providing more detailed information to cancer patients. Finally, Tyler and Snyder [65] found a similar association for the documentation of family history when comparing faculty physicians and residents. Generally, evidence for this predictor is strong enough.

Source of Information. McCahon et al. [46] found that a lack of specialized service availability was a barrier to RC. Moreover, consultation with a university-affiliated physician [64] or assistance from genetic counselors, nurse geneticists, or other physician extenders to assist with counseling [62] was a facilitator of RC. The evidence seems sufficient to support the effects of this predictor on RC.

Predictors for both RP and RC

Age. Being a physician older than either 50 or 65 years of age was found to be a barrier to genetic counseling taken as a comprehensive process and for both RP and RC when considered separately [19,53,61]. Moreover, 45 years of age appeared to be a critical threshold. There is sufficient evidence about the effect of this predictor.

Gender. Female physicians were more active in communicating genetic risk and to start a RP process, including estimation of the genetic risks, ordering a genetic test, or referring a patient for genetic testing [43,52,57]. However, the results on the involvement of male physicians in RP were inconclusive, as the studies found that male gender could be either a barrier or a facilitator on the RC or RP processes [53,57]. There is enough evidence for female but not for the male physicians (gender of the doctors as a predictor for RP and RC).

Organizational Affiliation. In one study [66], clinicians working in a clinical setting that is affiliated with an integrated health system were shown to be more likely to use cancer susceptibility testing than in unaffiliated practices. Kaplan et al. [43] established a positive association between referral for genetic testing with a physician's affiliation with a university. They also found a negative association between the initiation of counseling and working in a Health Maintenance Organization [43]. Thus, the assumption was that physicians who are affiliated to a genetic center were more compliant with the referral of patients for genetic testing. It seems that there is sufficient evidence to support these correlations.

Geographic Location. Literature has shown differences among countries (Southern, Eastern, Northern and Western European countries) [67]. Practicing in an urban region [52] or in some rural regions as defined by their localization (North-eastern and Midwestern US regions [19]) was also found to be a facilitator especially for RP. The evidence to support the effect of these predictors is adequate.

Number of Years of Practice/Seniority. One study found that higher rates of RP practice, such as recording family history for inherited health problems, were associated with fewer years in practice [55]. McCahon et al. [46] found that recently certified clinicians were more likely to deliver RP genetics services for common disorders. Moreover, one study showed that a post-qualification period ≤10 years was positively associated with referral practices [63], while another showed a positive linear association between the number of years since certification and RP [57]. These results showed a trend in knowledge, with a difference between older and more recent studies. Studies published before 2000 showed a negative association between the number of years since qualification and RC or RP; while on the contrary, more recent studies showed a positive association between the same parameters. Our assumption is that with the growing knowledge about genetics and the development of new testing technologies, physicians are more comfortable with RC and RP. There is adequate evidence to support the effects of this type of variables.

Past Experiences with Cancer and Patients. Professional and personal experience was found to be a facilitator of RC and RP either on the ordering or the referral practices. The items used by authors to measure past experiences were, for example, exposure to cancer diagnoses [43], personal experience with patients [50], past experience of RC [67] or RP [61,] as well as a personal history of cancer [43] or history of a relative with cancer [68]. Besides, one study reported that having a family member with breast cancer, in addition to its association with a greater knowledge of breast cancer risk factors, was associated with the utilization of software for breast cancer risk assessment [68]. Past experiences seemed to influence MGC-BC; however, more investigations are needed to better understand the association between past experiences with breast cancer and MGC-BC in order to develop specific strategies to increase the awareness of physicians, especially through their exposure to patients with breast cancer during their clinical training or continuing medical education programs. The evidence for supporting the effects of this variable seems insufficient.

Model of Practice. The literature showed that the profile of practice has an impact on MGC-BC. Indeed, clinicians may choose to adopt a practice profile that is prevention-oriented. Thus, physicians who frequently collected and recorded their patient medical history, diet information and are engaged in prevention counseling were more likely to report ordering genetic testing [66]. However, an assignment of higher priority to other health concerns was found to be a barrier to RP in the case of colorectal cancer screening [53] and has also been found to be related to a negative attitude toward routine provision of primary care genetic services by GPs [46]. It sounds that there is enough evidence regarding the effect of ‘model of practice' as a predictor of RC and RP.

Self-Confidence: Perceived Knowledge Skills. Freedman et al. [61 ]and Wideroff et al. [22] found that feeling qualified or prepared to recommend or advise patients for cancer susceptibility testing was positively associated with RC and RP. Furthermore, Carroll et al. [52] showed that high confidence in the knowledge of referral criteria and in core competences in genetics (e.g. family history recording, risk assessment for hereditary breast and colorectal cancers) were facilitators of referral practices. The evidence to support the effect of these predictors is adequate.

Self-Confidence: Perceived Communication Skills. Verger et al. [50] showed that difficulties in communication were barriers to breast cancer screening, as they can impair the process of obtaining cooperation and/or consent from patients. There is enough evidence to support these correlations.

Attitudes. The literature also showed that RC is positively associated with a positive attitude towards genetic susceptibility testing [60]. However, negative attitudes toward health insurance issues (i.e. loss of insurance) related to genetic testing for cancer susceptibility [61] were found to be barriers to RC. There is sufficient evidence about the effect of this predictor.

Perceived Roles. The perceived role of the professional has been identified as a predictor of RC. Escher and Sapino [60] found that physicians who felt that they have an active role in the pre-test procedure, the disclosure of results, and long-term follow-up were better in RC. Though, Kaplan et al. [43] found that the perceived role of physicians was negatively associated with the initiation of counseling as well as referral for genetic evaluation. The evidence for supporting the effects of this variable seems insufficient.

Medical Knowledge: Country of Graduation. Freedman et al. [61] found that US physicians having graduated from international medical schools (vs. US schools) were more likely to report feeling competent to recommend genetic testing to their patients. However, the latter were more likely to have a negative attitude towards the clinical utility of genetic tests for cancer susceptibility with respect to risk analysis, cost-effectiveness, and accuracy. Wideroff et al. [22] studied RP (ordering and referral) and found that being a foreign medical school graduate is inversely related to the use of cancer susceptibility testing among tertiary care physicians in the USA. International medical graduates were more likely to discuss the genetic risk but less likely to order or refer for genetic testing [22]. The evidence is not enough to strongly support the relation of this predictor to RP and/or RC.

Medical Knowledge: Medical Specialty. Many studies have explored the link between medical specialty and RC or RP. However, geneticists indicated a higher tolerance for ambiguity in their reported practices regarding genetic testing [69]. With regard to RP ordering practices, physicians in some specialties were less likely to order a genetic test, such as family practitioners [19], while others were more likely to order such tests, such as tertiary care physicians [61], obstetricians/gynecologists [51,68], and oncologists [61]. In the case of referral practices, the specialties that were more likely to refer were family practice [19] and obstetrics/gynecology [43,63,68,70]. There is enough evidence that advocates the effects of this variable.

Medical Knowledge: Training. Finally, another important predictor of the RP and RC processes is the training which the doctors received in medical school or in continuing medical education courses. McCahon et al. [46] found that a lack of training in genetic medicine was a barrier with respect to RC and RP. The supporting evidence for this factor is sufficient.

Medical Knowledge: Clinical Competences. With respect to competences, investigators have shown that knowledge of the characteristics and probabilities of cancers were positively associated with RC [38,59], RP ordering [51,66,71], and RP referral [18]. The latter findings were supported by the study of McCahon et al. [46] which reported that a negative knowledge score influences GP abilities to provide genetic services. There is strong enough evidence to support these effects.

Health System Knowledge. Knowledge about macro- and micro-level health system components had been found to be critical for RP and RC. Awareness of important specific aspects of the health system such as protective legislations (e.g. confidentiality, equity) was associated with RC and RP [19]. Moreover, when clinicians were aware of the location of genetic services [52] or local service availability [22], they were more likely ready to provide RC and RP. Carroll et al. [52] pointed out that differences that may exist among medical genetic counseling practices were partly related to the level of awareness of the services which were available for different diseases. For example, the latter investigators noticed that in the particular population studied, clinicians were less aware of services for hereditary colorectal cancer than for hereditary breast/ovarian cancer. The supporting evidence regarding this type of variables seems sufficient.

Source of Information. Advertising materials on cancer susceptibility testing, received during the previous year, was also a facilitator of RP [22]. Overall, the diversity of sources of information appeared to be a good predictor of RC and RP. The evidence to support this predictor's effect on RP and RC is adequate.

According to the 2011 National Comprehensive Cancer Network (NCCN) Guidelines entitled ‘Genetic/Familial High-Risk Assessment: Breast and Ovarian', women diagnosed with breast cancer prior to the age of 50 years should be referred for further risk assessment, genetic counseling, and possible genetic testing [72]. NCCN more recently published more detailed criteria for consideration of BRCA1/2 genetic testing [73]. This scoping review aimed to identify behavioral predictors of MGC-BC among medical doctors. Anticipating the paucity of evidence describing determinants of medical doctors' MGC-BC behavior, we also sought indirect evidence from other genetic diseases. The inductive analysis of 31 retrieved articles was performed and allowed the extraction of 193 predictors that were classified into 6 categories: (1) demographic, (2) organizational, (3) experiential, (4) professional, (5) psychological, and (6) cognitive.

With regard to those variables, studies have shown that practices vary across individuals, disciplines, and contexts [19,53,61]. However, we have identified relevant evidence. Indeed, determinants consistently associated with RC notably included seniority, prevention- oriented practices, and feeling qualified or prepared to counsel or recommend genetic tests. Determinants consistently associated with RP included positive attitudes toward genetic testing, knowledge about benefits, and affiliation to an integrated health care system. Some categories of factors, such as past experiences with the disease, were found to be facilitators of the whole process, either RC or RP, in the case of breast cancer [68,] while some others were found to be barriers, such as the lack of genetic training [21,56].

Literature revealed contradictory results for religion/spirituality factors. Indeed, cancer is often linked to death and fatal diagnosis where religion/spirituality may play a major role. A proportion of breast cancer is hereditary and may involve aspects of victimization or a feeling of guilt that can have a religious or spiritual substratum. Medical doctors may not be comfortable with these aspects. Further research is needed to study physicians' religious affiliation and its impact on MCG-BC (performance and efficacy) and to develop breast cancer genetic risk communication tools that are sensitive to religion/spirituality.

The perceived inadequacy of undergraduate and postgraduate genetic education was emphasized in some studies [19,21,54] and suggested that development and presentation of cancer-related genetic courses should be favored in medical schools. Recent studies confirmed that genetic training and specific guidelines have a high influence on a physician's decision to undertake genetic testing [74]. However, as noted by McCahon et al. [46], some medical doctors may not offer MGC-BC even with previous appropriate training. Resistance to change can be related to perceptions of one's roles and responsibilities.

Battista et al. [12] reviewed the literature to explore major conditions for the implementation of genetic services in healthcare systems and found that the reconfiguration of professional roles and responsibilities is among the most important challenges in the reorganization of genetic services and clinical practice changes. Our results showed that medical doctors, who are affiliated to a genetic center, were more compliant with the referral of patients for genetic testing. Therefore, a thorough study of organizational factors may contribute to understand how genetic center services should ideally be linked to primary care clinical settings as well as the distinctive qualities that these services should have regarding the risk assessment and the themes of communication.

A major limitation that we had in the development of specific recommendations was the lack of homogenous evidence and the occurrence of conflicting evidence. The selected studies were heterogeneous in terms of targeted population (GPs and doctors with different specialties), inconsistency of concepts definition (e.g. family history collection was part of the RC), study designs used (randomized clinical trials, cohorts, and cross-sectional surveys), or organizational context (i.e. healthcare system). Moreover, the studies considered in this scoping review were not only related to breast cancer (56%) but also addressed other genetic diseases or disorders such as colorectal cancer [49] or cystic fibrosis [38]. Among the 9 studies identified regarding predictors for RC, only 2 had investigated genetic risk communication in a context of breast cancer [69,70]. The heterogeneity of studies selected prevents sound specific recommendations from being drawn. However, generic recommendations are provided.

Another inherent limitation of this scoping review was that the recommendations were based on quantitative studies only. However, qualitative data are context sensitive with weak external validity and were thus excluded from this review. Therefore, future conceptual and theoretical research should synthesize qualitative data to build a comprehensive theoretical framework that may advise quantitative studies

On the other hand, we found a paucity of articles that explored genetic counseling (specific genetic risk prediction and communication) from the perspective of medical doctors (authors usually explore patients' perspective, needs, and expectations). Thus, there is an urgent need to organize research activities to better understand not only the actual clinical practices but also the needed skills, trainings, competencies, attitudes, perceptions, and receptiveness of MDs (especially those in primary care clinical settings) in terms of RP and RC in a context of MGC-BC. In the future, we should focus our research on the areas that can be changed over time with considering some specific training courses and educative activities to increase the willingness and professional ability and skills of the physicians regarding genetic counseling. In addition, future research should identify the important elements involved in the effective training of young doctors in medical schools and medical specialty (residency) programs.

As the patients become more informed on genetic aspects of many diseases (www.breastcancer.org), primary care physicians at the front-line of health care access will be more and more called to deliver genetic counseling/testing and to talk about genetic risk prediction/surveillance with their patients. This will be increasingly true as the field of public health genomics and personalized prevention through risk stratification at a population level will expand [9,10]. However, few strategies have been put into action to support clinical practices. In this review, we have found emerging evidence to support MGC-BC in primary care. These results offer relevant information that can be used to support MGC-BC performance among primary care physicians.

Based on our results, we recommend actions which can be considered for 2 sections: medical competences and healthcare management.

Strategies targeting medical competences include training and educational efforts emphasizing family history collection, genetic counseling for individuals at risk for inherited cancer, harms and benefits of genetic testing, and risk surveillance/management options. Strategies targeting healthcare management should include clarification of genetic testing referral procedures, clarification and standardization of roles and responsibilities in genetic counseling, referrals for testing and ordering genetic tests, and creation of effective channels of communication between genetic centers and primary care clinical settings, especially for those in solo practices. However, with limited data to discern evidence on patients' outcomes, it is difficult to provide clear guidance to clinicians and managers regarding advice on the specific strategies to be implemented in this area.

Given the gap in research in the area of MGC-BC, there should be a strategic investment in building research capacity to address relevant questions related to MGC-BC in primary care [75,76]. We suggest that future studies need to explore MGC-BC predictors through randomized controlled trials and observational studies with larger samples to explore the effect of these determinants in a real clinical context. Most studies were conducted in clinical settings but did not include patients; prospective trials should collect data and undertake dualistic analysis of MGC-BC as a shared decision-making process; the decision making that both the doctor and the patient are involved in it. Indeed, MGC-BC is a social interaction where multiple factors may interfere (e.g. interpersonal, cognitive, and spiritual dimensions). Thus, randomized clinical trials should focus on meaningful clinical outcomes and provide precise determinants of clinical effectiveness and patients' satisfaction. In an era of personalized medicine, this evidence is a cornerstone for targeting shared decision-making support tools and personalized services for MGC-BC in primary care.

In Canada, we need more studies, especially the ones that include real clinical environments and settings. By having more statistic data, we can organize our healthcare systems better to serve the people. Particularly, at the family practice level we need more comprehensive study results to be able to develop guidelines for genetic risk prediction and communication and to help the primary care physicians making decisions more easily and reliably regarding when and where to refer patients for genetic counseling or to discuss the risks with them.

We are grateful to Dr. Richard Poulin for the linguistic review. His thorough review and suggestions definitely helped to improve the quality of the manuscript.

This research was supported by the Canadian Institutes of Health Research as a part of the CIHR Team in Familial Risks of Breast Cancer Grant (CRN-8752-1) and the Ministry of Economic Development, Innovation and Export Trade of Quebec - grant #PSR-SIIRI-701.

1.
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Murray AJ, Davies DM: The genetics of breast cancer. Surg Annu 2013;31:1-3.
3.
Beaulieu N, Bloom D, Bloom R, Stein R: Breakaway: the global burden of cancer - challenges and opportunities. A report from the economist intelligence unit, 2009. The Economist 2009. http://www.livestrong.org/pdfs/GlobalEconomicImpact.
4.
Apostolou P, Fostira F: Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013;2013:747318.
5.
Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD: Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 2011;20:2105-2114.
6.
Lynch HT, Snyder C, Lynch J: Hereditary breast cancer: practical pursuit for clinical translation. Ann Surg Oncol 2012;19:1723-1731.
7.
Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O: Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013;208:329.e1-e6.
8.
Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH: Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns 2005;56:182-191.
9.
Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P: Public health implications from cogs and potential for risk stratification and screening. Nat Genet 2013;45:349-351.
10.
Pashayan N, Hall A, Chowdhury S, Dent T, Pharoah P, Burton H: Public health genomics and personalized prevention: lessons from the cogs project. J Intern Med 2013;274:451-456.
11.
Sivell S, Elwyn G, Gaff CL, Clarke AJ, Iredale R, Shaw C, Dundon J, Thornton H, Edwards A: How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review. J Genet Couns 2008;17:30-63.
12.
Battista R, Blancquaert I, Laberge AM, van Schendel N, Leduc N: Genetics in health care: an overview of current and emerging models. Public Health Genomics 2012;15:34-45.
13.
Berliner JL, Fay AM: Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Couns 2007;16:241-260.
14.
Smerecnik CMR, Mesters I, Verweij E, de Vries NK, de Vries H: A systematic review of the impact of genetic counseling on risk perception accuracy. J Genet Couns 2009;18:217-228.
15.
Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A: Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not. Patient Educ Couns 2012;86:239-251.
16.
Meiser B, Tucker K, Friedlander M, Barlow-Stewart K, Lobb E, Saunders C, Mitchell G: Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 2008;10:216.
17.
O'Daniel JM: The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors. J Genet Couns 2010;19:315-327.
18.
Aalfs CM, Smets EMA, De Haes HM, Leschot NJ: Referral for genetic counselling during pregnancy: limited alertness and awareness about genetic risk factors among GPs. Fam Pract 2003;20:135-141.
19.
Shields AE, Burke W, Levy DE: Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med 2008;10:404-414.
20.
Guerra CE, Jacobs SE, Holmes JH, Shea JA: Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med 2007;22:901-907.
21.
Qureshi N, Armstrong S, Modell B: GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 2006;23:106-110.
22.
Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, Croyle RT, Ballard-Barbash R: Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003;12:295-303.
23.
Graves KD, Christopher J, Harrison TM, Peshkin BN, Isaacs C, Sheppard VB: Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American women. J Genet Couns 2011;20:674-689.
24.
Pieterse AH, Ausems MG, Spreeuwenberg P, van Dulmen S: Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. Patient Educ Couns 2011;85:425-431.
25.
Chivers SK, Addington-Hall J, Lucassen AM, Foster CL: What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 2010;19:330-342.
26.
Edwards A, Gray J, Clarke A, Dundon J, Elwyn G, Gaff C, Hood K, Iredale R, Sivell S, Shaw C: Interventions to improve risk communication in clinical genetics: systematic review. Patient Educ Couns 2008;71:4-25.
27.
Howard AF, Balneaves LG, Bottorff JL: Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. J Genet Couns 2009;18:578-597.
28.
Arksey H, O'Malley L: Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19-32.
29.
Tinsley HEA, Weiss DJ: Interrater reliability and agreement of subjective judgements. J Couns Psychol 1975;22:358-376.
30.
Dewey ME: Coefficients of agreement. Br J Psychiatry 1983;143:487-489.
31.
Kottner J: Interrater reliability and the kappa statistic: a comment on Morris et al. (2008). Int J Nurs Stud 2009;46:140-141.
32.
Sim J, Wright CC: The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85:257-325.
33.
Brennan PF, Hays BJ: The kappa statistic for establishing interrater reliability in the secondary analysis of qualitative clinical data. Res Nurs Health 1992;15:153-161.
34.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
35.
Tinsley HEA, Weiss DJ: Interrater reliability and agreement; in Tinsley HEA, Brown SD (eds): Handbook of Applied Multivariate Statistics and Mathematical Modeling. San Diego, Academic Press, 2000, pp 95-124.
36.
Godin G, Bélanger-Gravel A, Eccles M, Grimshaw J: Healthcare professionals' intentions and behaviours: a systematic review of studies based on social cognitive theories. Implement Sci 2008;3:1-12.
37.
Landry R: Knowledge transfer as a value creation process: Proceedings from the 17th International Conference on Management of Technology, IAMOT on Creating and Managing a Knowledge Economy. Dubai, UAE, 2008. http://www.buid.ac.ae/iamot2008/.
38.
Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA: Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 1994;50:1-11.
39.
Littell JH, Corcoran J, Pillai V: Systematic reviews and meta-analysis. Oxford, Oxford University Press, 2008.
40.
Légaré F, Ratté S, Gravel K, Graham ID: Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions. Patient Educ Couns 2008;73:526-535.
41.
Ryhanen AM, Siekkinen M, Rankinen S, Korvenranta H, Leino-Kilpi H: The effects of internet or interactive computer-based patient education in the field of breast cancer: a systematic literature review. Patient Educ Couns 2010;79:5-13.
42.
St-Jacques S, Grenier S, Charland M, Forest JC, Rousseau F, Legare F: Decisional needs assessment regarding Down syndrome prenatal testing: a systematic review of the perceptions of women, their partners and health professionals. Prenat Diagn 2008;28:1183-1203.
43.
Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE: Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41:7-15.
44.
Poppelaars FAM, Adèr HJ, Cornel MC, Henneman L, Hermens RPMG, van der Wal G, ten Kate LP: Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. J Genet Couns 2004;13:31-44.
45.
Thomassen R, Tibben A, Niermeijer MF, Van Der Does E, Van De Kamp JJ, Verhage F: Attitudes of Dutch general practitioners towards presymptomatic DNA-testing for Huntington disease. Clin Genet 1993;43:63-68.
46.
McCahon D, Holder R, Metcalfe A, Clifford S, Gill P, Cole T, Sleightholme HV, Wilson S: General practitioners' attitudes to assessment of genetic risk of common disorders in routine primary care. Clin Genet 2009;76:544-551.
47.
Hindorff LA, Burke W, Laberge AM, Rice KM, Lumley T, Leppig K, Rosendaal FR, Larson EB, Psaty BM: Motivating factors for physician ordering of Factor V Leiden genetic tests. Arch Intern Med 2009;169:68-74.
48.
Kyne G, Maxwell S, Brameld K, Harrison K, Goldblatt J, O'Leary P: Compliance with professional guidelines with reference to familial cancer services. Aust NZJ Public Health 2011;35:226-230.
49.
Clasen CM, Vernon SW, Mullen PD, Jackson GL: A survey of physician beliefs and self-reported practices concerning screening for early detection of cancer. Soc Sci Med 1994;39:841-849.
50.
Verger P, Aulagnier M, Souville M, Ravaud JF, Lussault PY, Garnier JP, Paraponaris A: Women with disabilities: general practitioners and breast cancer screening. Am J Prevent Med 2005;28:215-220.
51.
Keller B, Zemp Stutz E, Tibblin M, Ackermann-Liebrich U, Faisst K, Probst-Hensch N: Screening mammographies in Switzerland: what makes female and male physicians prescribe them? Swiss Med Wkly 2001;131:311-319.
52.
Carroll JC, Cappelli M, Miller F, Wilson BJ, Grunfeld E, Peeters C, Hunter AG, Gilpin C, Prakash P: Genetic services for hereditary breast/ovarian and colorectal cancers - physicians' awareness, use and satisfaction. Community Genet 2008;11:43-51.
53.
Dulai GS, Farmer MM, Ganz PA, Bernaards CA, Qi K, Dietrich AJ, Bastani R, Belman MJ, Kahn KL: Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer 2004;100:1843-1852.
54.
Foo W, Young JM, Solomon MJ, Wright CM: Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis 2009;11:450-455.
55.
Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC: Family history-taking in community family practice: implications for genetic screening. Genet Med 2000;2:180-185.
56.
Lazcano-Ponce E, Angeles-Llerenas A, Alvarez-Del Rio A, Salazar-Martinez E, Allen B, Hernandez-Avila M, Kraus A: Ethics and communication between physicians and their patients with cancer, HIV/AIDS, and rheumatoid arthritis in Mexico. Arch Med Res 2004;35:66-75.
57.
McCann S, MacAuley D, Barnett Y: Genetic consultations in primary care: GPs' responses to three scenarios. Scand J Prim Health Care 2005;23:109-114.
58.
Wolf MS, Baker DW, Makoul G: Physician-patient communication about colorectal cancer screening. J Gen Intern Med 2007;22:1493-1499.
59.
Geller G, Tambor ES, Chase GA, Hofman KJ, Faden RR, Holtzman NA: Incorporation of genetics in primary care practice: will physicians do the counseling and will they be directive? Arch Fam Med 1993;2:1119-1125.
60.
Escher M, Sapino A-P: Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 2000;11:1131-1135.
61.
Freedman AN, Wideroff L, Olson L, Davis W, Klabunde C, Srinath KP, Reeve BB, Croyle RT, Ballard-Barbash R: US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 2003;120A:63-71.
62.
Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE: Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008;26:5789-5796.
63.
Acton RT, Burst NM, Casebeer L, Ferguson SM, Greene P, Laird BL, Leviton L: Knowledge, attitudes, and behaviors of Alabama's primary care physicians regarding cancer genetics. Acad Med 2000;75:850-852.
64.
Haas JS, Kaplan CP, Gregorich SE, Perez-Stable EJ, Des Jarlais G: Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? J Gen Intern Med 2004;19:302-309.
65.
Tyler CV Jr, Snyder CW: Cancer risk assessment: examining the family physician's role. J Am Board Fam Med 2006;19:468-477.
66.
Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N: Use of cancer susceptibility testing among primary care physicians. Clin Genet 2003;64:355-360.
67.
Borry P, Goffin T, Nys H, Dierickx K: Attitudes regarding predictive genetic testing in minors: a survey of European clinical geneticists. Am J Med Genet C Semin Med Genet 2008;148C:78-83.
68.
Guerra CE, Sherman M, Armstrong K: Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med 2009;22:272-279.
69.
Geller G, Tambor ES, Chase GA, Holtzman NA: Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care 1993;31:989-1001.
70.
Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ: Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 2009;13:735-741.
71.
Costanza ME, Stoddard AM, Zapka JG, Gaw VP, Barth R: Physician compliance with mammography guidelines: barriers and enhancers. J Am Board Fam Pract 1992;5:143-152.
72.
National Comprehensive Cancer Network: NCCN guidelines for detection, prevention, & risk reduction, genetic/familial high-risk assessment: Breast and ovarian, 2011. www.nccn.org/index.asp.
73.
National Comprehensive Cancer Network: Criteria for consideration of BRCA1/2 genetic testing, 2013. www.nccn.org.
74.
Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA: Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genet Med 2012;14:520-526.
75.
Haga SB, Burke W, Agans R: Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine? Genet Med 2013;15:513-514.
76.
Wood M, Flynn B, Stockdale A: Primary care physician management, referral, and relations with specialists concerning patients at risk for cancer due to family history. Public Health Genomics 2013;16:75-82.
77.
Gorin SS, Ashford AR, Lantigua R, Hajiani F, Franco R, Heck JE, Gemson D: Intraurban influences on physician colorectal cancer screening practices. J Natl Med Assoc 2007;99:1371-1380.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.